FBXO11 targets BCL6, a transcription factor critical in B-cell development, for ubiquitin-dependent degradation, and FBXO11 loss leads to upregulation of BCL6, a common finding in DLBCL. Here, BCL6 is linked to diffuse large B-cell lymphoma.